Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Skeletal-Related Events In Myeloma: A Population-Based Study

John Ashcroft, MD, MBBChir, PhD, MRCP, MA, FRCPath, Bagguley Timothy, MSc, Alexandra Smith, PhD, Han-I Wang, PhD, Debra Howell, PhD, Hazem A Sayala, MBChB, MRCP, Gordon Cook, MD, PhD, Andrew Jack, PhD, Russell Patmore, MD, Eve Roman, PhD

Blood (2013) 122 (21): 3158.

https://doi.org/10.1182/blood.V122.21.3158.3158

Published: 2013

Journal Articles

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Abraham M Varghese, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, Richard A Jones, Andy Rawstron, PhD, J Sheila, Paul Evans, Carter Anthony, Claire E. Dearden, MD, Estella Matutes, Andrew R. Pettitt, PhD, MRCPath, Daniel B. Kennedy, Sharon Barrans, Lisa Worrillow, Peter Hillmen, MBChB, FRCP, FRCPath, PhD

Blood (2010) 116 (21): 922.

https://doi.org/10.1182/blood.V116.21.922.922

Published: 2010

Journal Articles

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A. Follows, Donald Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David G. Oscier, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Andy Rawstron, PhD, Christopher F.E. Pocock, MD, PhD

Blood (2010) 116 (21): 697.

https://doi.org/10.1182/blood.V116.21.697.697

Published: 2010

Journal Articles

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Peter Hillmen, MB, ChB, PhD, John G. Gribben, MD, DSc, George A Follows, Donald W. Milligan, MD, MBChB, Hazem A. Sayala, MBChB, MRCP, Paul Moreton, David Oscier, MD, Claire E. Dearden, MD, Daniel B. Kennedy, Andrew R. Pettitt, PhD, MRCPath, Amit Nathwani, MD, PhD, Dena Cohen, Walter M Gregory, Andy C. Rawstron, PhD, Colin R.W. Hayward, MBBS, Christopher Pocock

Blood (2009) 114 (22): 3428.

https://doi.org/10.1182/blood.V114.22.3428.3428

Published: 2009

Journal Articles

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

Hazem A. Sayala, Paul Moreton, Ben Kennedy, Guy Lucas, Michael Leach, Saad M.B. Rassam, Andrew Haynes, Jane Tighe, David G. Oscier, Christopher Fegan, Andy C. Rawstron, Peter Hillmen

Blood (2007) 110 (11): 3114.

https://doi.org/10.1182/blood.V110.11.3114.3114

Published: 2007

Journal Articles

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

Peter Hillmen, MBChB, PhD, Christopher Pocock, MB, BS, PhD, Dena Cohen, MSc, Kim Cocks, MSc, Hazem A. Sayala, MB, BCh, Andy Rawstron, PhD, Daniel B. Kennedy, MB, ChB, Christopher Fegan, MB, BS, Don W. Milligan, MB, ChB, Claire Dearden, MB, BS, Alexandra Smith, BSc, Emma Lindop, BSc, Andrew R. Pettitt, MB, BChir, PhD

Blood (2007) 110 (11): 752.

https://doi.org/10.1182/blood.V110.11.752.752

Published: 2007

Journal Articles

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

Hazem A. Sayala, MD, Paul Moreton, MD, Richard A. Jones, PhD, Andy C. Rawstron, PhD, Sheila J. O’Connor, PhD, Paul Evans, PhD, Carter Anthony, MsC, Claire Dearden, MD, Estella Matutes, MD, PhD, Andrew R. Pettitt, MD, PhD, Daniel B. Kennedy, MD, Peter Hillmen, MD, PhD

Blood (2006) 108 (11): 34.

https://doi.org/10.1182/blood.V108.11.34.34

Published: 2006

Journal Articles

EBV Related Transformation Events in CLL.

Hazem A. Sayala, MD, Sheila J. O’Connor, PhD, Andrew S. Jack, PhD, Chetan Patalappa, Peter Hillmen, MD, PhD, Roger G. Owen, MD

Blood (2006) 108 (11): 4963.

https://doi.org/10.1182/blood.V108.11.4963.4963

Published: 2006

NARROW

Skeletal-Related Events In Myeloma: A Population-Based Study

Long Term Survival Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab In Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group)

Rituximab Plus Chlorambucil In Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukemia (CLL): Final Response Analysis of An Open-Label Phase II Study

An Open-Label Phase II Study to Investigate the Safety and Efficacy of Rituximab Plus Chlorambucil in Previously Untreated Patients with CD20-Positive B-Cell Chronic Lymphocytic Leukaemia (CLL).

Eradication of Minimal Residual Disease with Alemtuzumab in Chronic Lymphocytic Leukemia Is Associated with Prolonged Survival and Is an Appropriate Theraputic Endpoint for Relapsed CLL.

NCRI CLL201 Trial: A Randomized Phase II Trial of Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) with or without Rituximab in Previously Treated CLL.

Final Report of the UKCLL02 Trial: A Phase II Study of Subcutaneous Alemtuzumab Plus Fludarabine in Patients with Fludarabine Refractory CLL (on Behalf of the NCRI CLL Trials Sub-Group).

EBV Related Transformation Events in CLL.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only